Surgical Information Systems LLC (SIS) is a healthcare technology company that provides IT solutions to improve patient care and hospital workflow efficiency. The company specializes in perioperative information systems for surgery departments, which help manage surgical processes and data.

Surgical Information Systems LLC (SIS)

SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. 

Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.

Alumni Ventures

Intuitive Ventures

Pitango VC

Camford Capital

Cancer Research Institute

Khosla Ventures

National Cancer Research Institute

DHVC

Green D Ventures

Piedmont Capital

Bioluminescence Ventures

Castor Ventures

KdT Ventures

SURGE Therapeutics

We are delighted to be recognized as "Immunomodulatory Solution of the Year" by BioTech Breakthrough! It's an honor to receive this award, alongside other great innovators in their respective spaces, such as BigHat Biosciences, Garuda Therapeutics, Mission Bio, Seer, Thermo Fisher Scientific, and Vaxess Technologies. Congratulations to everyone 🎉 
https://lnkd.in/e-X3PCvE

We are delighted to share that we have closed our $32M Series B, led by Bioluminescence Ventures, with participation from KdT Ventures, Robert Long, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute (CRI), Intuitive Ventures, Khosla Ventures, and Pitango. Our funding will enable us to generate proof-of-concept, event-free survival Phase 2a data for our lead program and to advance two additional programs through Phase 1. We hugely appreciate your visionary support, as we strive to revolutionize the standard of care for cancer patients in need.

https://lnkd.in/eahf3Cqs

We are delighted to share that we have dosed the first patients in our Phase 1/2a trial. This milestone represents the first ever administration of intraoperative immunotherapy in history. Ever. (Please let that sink in for a moment…or three.) We are so grateful to these patients and to all future patients for joining our mission to create a world where nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence. To this end, we hope to reimagine and augment the standard of care for solid tumors: SURGEry. Today, surgery is a physical intervention only – we believe that it should and can be a therapeutic intervention as well.

https://lnkd.in/g8Dd_2rN

COM:SURGETX

Surgical Information Systems LLC (SIS)